Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

FDA considers interim access for compounded peptides; Enspryng's label expansion

Plus news about Microbiotica, Cyrano Therapeutics and Opus Genetics. HHS and FDA submit peptide policy for review: An “interim access policy for compounding using certain peptides” is awaiting regulatory review at the White House Office ...

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

Read the original at endpoints.news →

More in Health & Medicine

More from Friday 16 October →